TABLE 2.
Results of clinical efficacy
| Overall (N = 25), n (%) | <4 cycles (n = 12), n (%) | ≥4 cycles (n = 13), n (%) | p‐value | |
|---|---|---|---|---|
| Best response | ||||
| CR | 0 (0%) | 0 (0%) | 0(0%) | — |
| PR | 12 (48.0%) | 2 (16.7%) | 10 (76.9%) | — |
| SD | 10 (40.0%) | 6 (50.0%) | 3 (23.1%) | — |
| PD | 3 (12.0%) | 4 (33.3%) | 0 (0%) | — |
| ORR, 95% CI | 48.0 (27.8–68.7)% | 16.7 (2.1–48.4)% | 76.9 (46.2–95.0)% | 0.007 |
| DCR, 95% CI | 88.0 (68.8–97.5) % | 75.0 (42.8–94.5) % | 100 (75.3–100)% | 0.007 |
Abbreviations: CR, complete remission; DCR, disease control rate; PR, partial remission; ORR, objective response rate; PD, progression disease; SD, stable disease; .